Clexio Biosciences
Mabel Arévalo has extensive work experience in the field of clinical pharmacology and drug development. Mabel is currently working as the Clinical Pharmacology and Biomarkers Director at Clexio Biosciences since September 2023. Prior to this, they held roles at Oryzon Genomics SA, where they served as the Clinical Pharmacology and Drug Development Director from May 2022 to August 2023, and as the PK/PD Development Platform Leader from September 2016 to April 2022. Before joining Oryzon Genomics SA, Mabel worked at Novartis Institutes for BioMedical Research as a Laboratory Head specializing in DMPK/NPKPD from November 2013 to October 2016. Mabel also gained experience as a Study Director and Head of Department for Pharmacokinetics and ADME at Harlan Laboratories, Inc. from November 2009 to October 2013. Mabel started their career as a Postdoctoral Researcher in Molecular and Cell Biology at PRBB (Barcelona Biomedical Research Park) from November 2008 to November 2009 and as a Predoctoral Researcher in Biomedicine at IRB Barcelona from April 2003 to October 2008.
Mabel Arévalo holds a PhD in Biomedicine from IRB Barcelona, completed from 2003 to 2008. Prior to that, they pursued a Master's in Experimental Pharmaceutical Sciences, Physiology and Pharmacokinetics at the Universitat de Barcelona from 2002 to 2003. Mabel also earned a Bachelor's degree in Biology and Biomedical Sciences from the same university from 1997 to 2002. Additionally, Mabel Arévalo attended the PKPD Gabrielsson course, although the specific dates and degrees obtained are not provided.
This person is not in any offices
Clexio Biosciences
Clexio Biosciences is a CNS-first clinical-stage pharmaceutical company. Our therapies are designed to address patients’ unmet needs through scientifically based integration of drugs with innovative technologies. Clexio’s growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including Major Depressive Disorder, Parkinson’s Disease, Pain and other conditions involving impairment of the neurological system. Patients, and what they are living with, are at the center of everything we do. Our passion is to find ways to help patients regain a sense of balance, health and a life worth living. Clexio’s team is comprised of a multi-disciplinary team with vast experience in drug development. We see our team and our partners as the key ingredients to our success. Join our vision to make lives of millions of patients worth living again.